The ground-breaking non-invasive prenatal test IONA developed by AIM-listed Premaitha Health has netted the company £2.5m in its first year of commercialisation. The Manchester-based biotech specialist said the income from IONA in its first year was at the upper end of revenue expectations.
Premaitha chief executive Dr Stephen Little said: “We are very encouraged by sales in our first year of trading and particularly the growth momentum that we take into the new financial year. A broader international footprint opens up opportunities in territories with differing competitive, regulatory and intellectual property landscapes. Overall, the NIPT marketplace is developing in the way we anticipated and we believe Premaitha’s ability to offer a complete CE-marked system represents a very significant opportunity.”
See the article in full at TheBusinessDesk.com